Systemic perfusion: a method of enhancing relative tumor uptake of radiolabeled monoclonal antibodies by Wahl, Richard L. et al.
NW/. Med. Bid. Vol. 15. No. 6, pp. 611-616, 1988 
hr. J. Radiaf. Appl. Insrrum. Part B 
Printed in Great Britain. All rights reserved 
0883-2897/88 S3.00+ 0.00 
Copyright c 1988 Pergamon Press plc 
Systemic Perfusion: a Method of Enhancing 
Relative Tumor Uptake of Radiolabeled 
Monoclonal Antibodies 
RICHARD L. WAHL,* CYNTHIA R. PIKO, BARBARA A. BEERS, 
ONELIO GEATTI, JON JOHNSON and PHIL SHERMAN 
Division of Nuclear Medicine, Department of Internal Medicine, University of Michigan Medical Center. 
Ann Arbor, MI 48109-0028, U.S.A. 
(Received 14 April 1988) 
We evaluated the feasibility of systemic vascular perfusion with saline (mimicking plasmapheresis) as a 
method to enhance tumor-specific monoclonal antibody (MoAb) tumor/background ratios. Initially, 
groups of rats were injected intravenously (i.v.) with i3’I-5G6.4 MoAb (mutine IgGZaK reactive with 
ovarian carcinoma). These animal’s radioactivity levels were determined by dose calibrator and they were 
imaged before and after perfusion which was conducted at 4 or 24 h post-antibody injection. Animals were 
sacrificed after perfusion, as were controls, and normal organ radioactivity levels determined. In addition, 
nude mice bearing HTB77 ovarian cancers subcutaneously were injected i.v. with 13’1-5G6.4 MoAb and 
were imaged before and after systemic perfusion with saline 24 h post-5G6.4 injection. Perfusion in rats 
dropped whole-body 566.4 levels significantly at both perfusion times (P < 0.0005). The drop in 
whole-body radioactivity with perfusion was significantly greater for the animals perfused at 4 h post i.v. 
566.4 antibody injection (48.3 + 5.1%) than for those perfused at 24 h post i.v. antibody injection 
(32.9 f. 2.9%) (P < 0.025). In the nude mice with ovarian cancer xenografts, y camera images of tumors 
were visually and quantitatively (by computer image analysis) enhanced by perfusion, with a 2.33-fold 
greater decline in whole body uptake than in the tumor (P < 0.05). These studies show that (1) much 
background antibody radioactivity can be removed using whole-body perfusion with saline, (2) that the 
decline in whole body activity is larger with 4 than 24 h perfusion and (3) tumor imaging can be enhanced 
by this approach. This and similar approaches that increase relative tumor antibody uptake such as 
plasmapheresis may be useful in imaging and therapy with radiolabeled antibodies. 
Introduction 
When intact monoclonal antibodies (MoAbs) are 
injected intravenously, peak absolute tumor uptakes 
of antibody are in the first 1-2 days post-injection 
(Goodwin, 1987). Imaging is not optimal until con- 
siderably later, as elevated levels of blood pool 
radioantibody persist for days following iv. intact 
antibody injection, and the resulting relatively low 
tumor/background ratios detract from the utility of 
intact MoAbs as imaging and therapeutic agents 
(Goodwin, 1987). Only as blood pool radioantibody 
levels clear do tumor/background ratios improve. 
Computer background subtraction methods, while 
improving diagnostic sensitivity in imaging studies, 
do not impact upon these low target/back- 
ground ratios for purposes of radioimmunotherapy 
(Goldenberg et al., 1978; Wahl et al., 1986b). While 
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antibody fragments do significantly enhance 
tumor/background ratios and allow for imaging at 
earlier time points than intact antibody, they result 
in less absolute radioantibody reacting the tumor 
than if intact antibody is used (Wahl et al., 1983). 
Alternative approaches to improving target/back- 
ground ratios, using polyclonal anti-mouse anti- 
bodies (either attached to liposomes or alone) to clear 
the primary radiolabeled antibody from the blood 
after maximal tumor uptake has been achieved, have 
been investigated, but can result in high levels of 
splenic and to a lesser extent hepatic activity (Regent 
et al., 1982; Sharkey et al., 1985). 
If it were possible to transiently have high 
blood levels of tumor-specific antibody following iv. 
injection, allowing antibody to accumulate in tumor, 
and then to rapidly remove bIood pool radioantibody 
without increasing reticuloendothelial system uptake, 
it might be possible to considerably enhance relative 
tumor uptake. This would obviously enhance 
imaging and increase the possibility of successful 
radioimmunotherapy with radiolabeled antibody. 
In the present study we evaluated the feasibility 
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of enhancing specific antibody tumor/background levels/g of injected antibody in selected tissues were 
ratios by experimentally attempting to achieve the 
total removal of circulating blood pool ratioantibody 
determined using standard tissue counting methods 
(Wahl et al., 1984). In nude mice with HTB77 tumors 
from normal and tumor-bearing animals by exhaus- 
tive perfusion with saline. While this approach is not 
established subcutaneously, the “‘1-5G6.4 was injec- 
compatible with life, such an approach, if enhancing 
ted Lv., and 24 h later perfusion was performed by 
removal of circulating blood, by cannulation and 
tumor/background ratios, would lay a logical frame- 
work for the more selective removal of radiolabeled 
saline perfusion of the right ventricle with drainage of 
blood from the tail vein, as well as subsequent left 
MoAbs from the blood, such as immuno-adsorption ventricular injection with removal of blood from the 
plasmapheresis, which can be performed in the living right heart. Gamma camera imaging was performed 
(Terman et al., 1979). using a GE400 AT y camera attached to a STAR 
computer before and after perfusion, using a 
Methods 128 x 128 image matrix, word mode, a fixed imaging 
Monoclonal antibody 
time of 10 min and a fixed y camera-to-animal 
imaging distance. Regions of interest for whole body 
566.4 is an IgG2ak murine MoAb reactive with with and without tumor were selected and analyzed. 
ovarian and other epithelial carcinomas (Wahl et al., A .high energy parallel hole collimator was used. 
1986a). It localizes specifically to ovarian cancer Statistical analysis was by ANOVA, the paired-t 
xenografts when administered intravenously (Wahl (when the animal was used as its own control) and the 
et al., 1985a). It was grown in Balb/c mice as ascites unpaired t-tests. 
and purified by staphylococcal protein A chro- 
matography (Ey et al., 1978). Purity was assured by 
SDS PAGE gels in the reduced and unreduced state Results 
(Laemmli, 1970). The antibody was labeled by the Systemic perfusion in rats was somewhat difficult 
iodogen (Pierce Chemical-Rockford, Ill.) method initially and even with practice could require 20 min 
using a 5-8/l antibody/iodogen ratio. Specific or longer per rat to complete. Difficulties with leak- 
activity of the injected preparations was approxi- age at the injection site were not uncommon, but 
mately 6pCi/pg. Separation of free from bound could largely be avoided by keeping the infusion rate 
iodine was by Biogel P-60 sizing chromatography. slow. The perfusion studies in the nude mice were far 
Greater than 95% freedom from contaminating more difficult than in the rat, as vascular access was 
iodine was demonstrated by silica gel TLC (Wahl et more difficult, and it was not possible to get as 
al., 1985b). Binding of the labeled protein to target complete a degree of perfusion in these animals. In 
cells was demonstrated by a 1 h direct binding assay spite of some of the technical difficulties, it was 
to HTB77 target cells (Wahl et al., 1985b; Lindmo et possible in the rats to get quite complete perfusion, 
al., 1984). as judged by the nearly “clear” fluid removed from 
Animal studies 
the opposite femoral vein by the conclusion of the 
perfusion, indicating that nearly all of the easily 
Healthy female Sprague-Dawley rats were used in accessible blood pool had been exchanged for saline. 
the rat studies, while athymic Swiss nude mice with Such complete perfusion was not achieved in the 
HTB77 S.C. ovarian carcinoma xenografts (which mice, however. 
occur 3-6 weeks post the S.C. injection of 10 million Whole-body activity in the rats as assessed by dose 
HTB77 cells) were used in the tumor-bearing animal calibrator reading of the entire animal before and 
studies. Four groups of five rats were injected iv. in after perfusion showed a clear drop when perfusion 
the femoral vein following cut down, with approxi- was done at 4h (17.7f0.14-9.14f0.94pCi, 
mately 19 FCi of 13’1-5G6.4. Perfusion of the normal mean f SEM) (P < 0.005) or at 24 h (13.18 +0.21- 
rats (which were under ether anesthesia during the 8.86 f 0.47 PCi) (P < 0.05). The post-perfusion 
study) was conducted by cannulation of the femoral whole-body activities as a percent of pre-perfusion 
vein with a butterfly needle, and slowly flushing with values (4 h post/pre = 51.7 + 5.1% vs 67.1 f 2.9%) 
heparitiized saline (approximately 100 cm3 of indicated that the animals perfused 4 h post-injection 
perfusate was used), with drainage of blood from the had a significantly greater decline in whole-body 
opposite femoral vein. Thus all organs, except the activity than animals perfused at 24 h post i.v. injec- 
injected leg, were well-perfused. The animals were tion (P < 0.25). Representative y camera images 
perfused until the effluent was nearly clear. Groups of several of the rats before [Fig. l(a)] and after 
of five rats were perfused 4 or 24 h following iv. [Fig. l(b)] perfusion additionally show this decline 
antibody injection, with images obtained before and in whole-body activity, in this case with perfusion 
after perfusion. Animals’ whole-body radioactivity performed at 4 h post i.v. antibody injection. 
level was also assessed in a dose calibrator both The percent of injected radioactivity detected/g of 
before and after systemic perfusion. Control groups tissue at sacrifice in the control and perfused groups 
of unperfused animals were also sacrificed at 4 and are shown in Table 1. Note that when perfusion was 
24 h following antibody injection. Radioactivity conducted at 4 h post i.v. antibody injection, the 
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Fig. I. (a) Gamma camera image 3f h post i.v. injection of 19 PCi of “‘1-5G6.4 antibody. Three rats are 
shown. (b) Immediately after whole body perfusion at 4 h post-i.v. injection. Note the considerably 
decreased whole body activity in (b). In five animals the mean post-perfusion whole-body activity was 
51.7 f 5.1% of the pre-perfusion activity. 
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(b) 
Fig. 2. (a) Twenty four hours post i.v. injection image of a representative nude mouse with a SC. ovarian 
carcinoma xenograft in the left shoulder region. Considerable whole-body background activity is present. 
(b) Immediately after perfusion, far clearer visualization of the tumor relative to background is seen. 
Activity in the lower portion of the animal is in the urinary bladder. In the group of animals studied, 
the drop in whole-body radioactivrity was 28.5 f 7.1% while the drop in tumor radioactivity was 2.33-fold 
less (12.1 f 5.7%) (P -c 0.05) based on computer quantitation of y camera images. 
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Table I. Normal rat perfusion vs controls 
(a) Sacrifice 4h post a&body injection 
Controls 4 h Perfusion 
Liver 0.133 * 0.007 0.054 + 0.007* 
Kidney 0.187 5 0.01 I 0.050 f o.oofP 
SpkIl 0.090 Yi 0.002 0.036 f 0.004’ 
Lltng 0.316 + 0.044 0.093 * 0.011* 
Leg muscle 0.007 * 0.000 0.019 + 0.007t 
S. bowel 0.126 & 0.006 0.042 + 0.006’ 
Blood 0.763 &- 0.083 ND 
*Significantly (P i 0.0005) less than control values. 
tNot perfused due to design of system. 
(b) Sacrifice 24h afirer in. anfibody injection 
Controls 24 h Perfusion 
Liver 0.065 + 0.002 0.038 f 0.004***’ 
Kidney 0.078 & 0.003 0.050 _+ 0.013 
Spleen 0.042 f 0.001 0.026 + 0.004” 
Lung 0.197 f 0.027 0.106 +0.020 
Leg muscle 0.014 + 0.001 0.01 I * o.oolt 
S. bowel 0.057 & 0.003 0.034 + 0.004*** 
Blood 0.420 f 0.027 ND 
****f <0.005 less than control values; ***P <O.Ol less 
than control values; **f < 0.025 less than control 
values. 
Mean + SEM post-perfusion and controls; (n = 5 
annnals/group); results: (%kg dose/g). 
declines in organ activity/g are significant at the 
P < 0.005 level (leg muscle was not perfused). Drops 
in tissue activity at 24 h following perfusion, relative 
to controls, were slightly less marked, though still 
significant (P in 0.01-0.1 range). The liver activity 
drop with 4 h perfusion (72%) is greater than with 
24 h perfusion (41 X) (P < O.Ol), compatible with the 
dose calibrator data. 
Having demonstrated a 33-50% drop in whole- 
body activity and a 5@-70% drop in normal organ 
activities in rats following systemic perfusion, the 
technique was then extended to nude mice with S.C. 
ovarian tumors present. This was considerably more 
demanding technically, as it was far more difficult to 
achieve satisfactory vascular access in the nude mice 
and thus the perfusion was less complete. After 
developing a somewhat optimized technique, the 
feasibility of the technique was tested in a group of 
nude mice which had HTB77 S.C. ovarian tumors. 
These animals were injected intravenously with 
3OpCi of “‘I-5G6.4 antibody. Twenty-four hours 
later they were imaged for identical time periods 
before and after perfusion with saline using a y 
camera with data recorded into a computer. Repre- 
sentative images using the same imaging parameters, 
are shown before [Fig. 2(a)] and after [Fig. 2(b)] 
perfusion. Tumor visualization is considerably en- 
hanced in the post-perfusion images, despite the fact 
that there is only a 28.5 k 7. I % drop in whole-body 
activity (based on whole body ROI, less tumor, 
mean + SEM of 4 animals pre- and post-perfusion) 
indicating that perfusion was probably incomplete 
relative to the rat data. The image enhancement 
apparent in the animal was due to the fact that tumor 
uptake dropped only 12.1 + 5.7% (based on tumor 
ROI data), considerably less than the whole-body 
activity drop (P < 0.05) resulting in improved 
tumor/non-tumor ratios. 
Discussion 
These feasibility studies clearly demonstrate that 
exhaustive perfusion with saline in the rat and less 
exhaustive perfusion in the nude mouse with ovarian 
carcinoma xenografts removes a significant amount 
of whole body radioantibody activity and enhances 
tumor imaging. Using this approach in rats, drops of 
up to 72% in liver activity were achieved with 
perfusion at 4 h and 41% at 24 h following iv. 
antibody injection. While the drops in whole animal 
activity were less in the normal mice (due to the 
difficulty of the procedure) than in the rats, they were 
sufficient to considerably enhance tumor imaging by 
improving quantitative tumor/background ratios on 
y scans. This enhancement occurred as tumor activity 
did not decline as much as whole-body activity with 
the antibody removal. 
The normal tissue activities dropped more at 4 h vs 
controls than they did after 24 h of the antibody 
circulating systemically. This was also true in the dose 
calibrator studies comparing the drop in whole-body 
activity in the experimental animals pre- and post- 
perfusion. This lesser drop, with equal amount of 
perfusate, is most likely due to the slow diffusion of 
radioantibody out of the immediately exchangeable 
blood pool following i.v. administration. Presumably 
less circulating antibody is easily accessible at later 
times. Consequently there was more difficulty 
removing antibody from the entire animal at 24 than 
4 h. It is probable that even larger drops in systemic 
radioantibody levels could be achieved if the 
perfusion could be carried out over a longer period 
of time, to enhance the transit of radioantibody 
from the extravascular to the vascular compartment, 
with subsequent removal of activity from the blood 
vessels. The magnitude of such enhancement, and 
the effect on tumor uptake, would need further 
evaluation as it is probable that tumor radioactivity 
levels might drop, in time, as well. 
It appears that the mechanism of the enhancement 
in tumor/non-tumor ratios by perfusion is due to the 
fact that specific antibody is retained at the tumor 
due to binding to the antigen in the tumor while 
blood pool antibody levels are more greatly reduced 
through perfusion. It is, of course, possible that some 
of the effect may be due to slower transit of antibody 
out of tumor interstices than from normal tissues. 
Additional studies, including dual-label studies 
would be necessary to more definitively address this 
mechanistic issue, though the fact remains that the 
tumor/background ratios are, at least acutely, en- 
hanced by perfusion. Studies in which the animals 
can live for a longer period of time following removal 
of circulating blood pool activity will also be neces- 
sary to evaluate the effect on whether the cumulative 
dose of radioactivity to tumors following the systemic 
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clearance is enhanced relative to the whole-body 
dose. 
While some loss of tumor radioactivity was seen in 
the quantitative y images with the l&fusion pro- 
cedure, it was less than whole body losses, indicating 
that tumor retention of antibody was greater than 
whole-body retention. This is the key to the tech- 
nique: the specific antibody remains associated with 
the tumor, but is washed away to a greater extent 
from normal tissues. We have recently applied a 
conceptually similar technique to lavage of specific 
antibody away from normal structures in the peri- 
toneal cavity, but have seen retention at the tumor 
(Wahl et al., 1987b). 
It is obvious that systemic perfusion in its present 
form, removal of the circulating blood pool activity 
by repeated injection with saline with resultant exsan- 
guination, is a technique that is not well-suited to 
clinical practice. Rather, it is a laboratory demonstra- 
tion of what might be possible if circulating radio- 
antibody is removed extracorporeally. The technique 
does not appear to result in high reticuloendothelial 
system levels of radioactivity, as can be seen with the 
polyclonal anti-mouse clearance technique, and 
seems to have considerable promise (Wahl and 
Fisher, 1987a). Plasmapheresis, and other more selec- 
tive blood cleansing processes, should have results 
similar to systemic perfusion and this study strongly 
suggests that such manipulations should considerably 
improve target/background ratios, and possibly in- 
crease therapeutic indices with radiolabeled anti- 
bodies (Terman et al., 1987). 
In conclusion, systemic perfusion with saline re- 
sults in a larger drop of whole-body radioantibody 
activity than tumor activity. This effect enhances 
tumor visualization on y scans and should lead to 
better therapeutic indices for radiolabeled antibodies, 
if functionally-similar techniques that are blood- 
sparing, can be applied. 
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